Immunic Inc (IMUX)

Currency in USD
16.580
+0.650(+4.08%)
Closed·
16.610+0.030(+0.18%)
·
Trading near 52-week High
IMUX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
15.71016.862
52 wk Range
0.58416.862
Key Statistics
Prev. Close
15.93
Open
16.07
Day's Range
15.71-16.862
52 wk Range
0.584-16.862
Volume
163.54K
Average Volume (3m)
197.46K
1-Year Change
99.9276%
Book Value / Share
9.37
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
IMUX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
41.900
Upside
+152.71%
Members' Sentiments
Bearish
Bullish
ProTips
4 analysts have revised their earnings upwards for the upcoming period

Immunic Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy

Analyst Ratings

11 Buy
0 Hold
0 Sell
Ratings:
11 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 41.900
(+152.71% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Stifel
Buy25.00+50.78%-MaintainMay 27, 2026
B.Riley
Buy27.00+62.85%40.00MaintainMay 22, 2026
Wolfe Research
Buy25.00+50.78%-New CoverageMay 22, 2026
H.C. Wainwright
Buy22.00+32.69%-MaintainMay 14, 2026
H.C. Wainwright
Buy22.00+32.69%5.00MaintainApr 30, 2026

Earnings

Latest Release
Aug 11, 2026
EPS / Forecast
-0.80 / -1.23
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

IMUX Income Statement

Compare IMUX to Peers and Sector

Metrics to compare
IMUX
Peers
Sector
Relationship
P/E Ratio
−2.0x−3.0x−0.3x
PEG Ratio
−0.03−0.010.00
Price/Book
1.8x2.2x2.6x
Price / LTM Sales
-7.2x3.1x
Upside (Analyst Target)
69.9%150.8%48.3%
Fair Value Upside
Unlock−3.3%6.7%Unlock

Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company also develops IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
1.75M12.83%27.83M
Other Institutional Investors
8.99M66.02%143.26M
Public Companies & Retail Investors
2.88M21.15%45.90M
Total
13.62M100.00%216.99M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Millennium Management LLC7.12%969,54715,445
Integrated Core Strategies (US) LLC7.05%960,81615,306

People Also Watch

141.16
SPCX
-3.41%
26.77
FLY
+0.87%
4.1600
EOSE
-1.89%
2.5400
SIDU
+2.42%
24.750
PL
+1.02%

FAQ

What Is the Immunic (IMUX) Stock Price Today?

The Immunic stock price today is 16.580 USD.

What Stock Exchange Does Immunic Trade On?

Immunic is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Immunic?

The stock symbol for Immunic is "IMUX."

What Is the Immunic Market Cap?

As of today, Immunic market cap is 226.660M USD.

What Is Immunic's Earnings Per Share (TTM)?

The Immunic EPS (TTM) is -3.998.

When Is the Next Immunic Earnings Date?

Immunic will release its next earnings report on Oct 29, 2026.

From a Technical Analysis Perspective, Is IMUX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Immunic Stock Split?

Immunic has split 2 times.

How Many Employees Does Immunic Have?

Immunic has 95 employees.

What is the current trading status of Immunic (IMUX)?

As of Aug 13, 2026, Immunic (IMUX) is trading at a price of 16.580 USD, with a previous close of 15.930 USD. The stock has fluctuated within a day range of 15.710 USD to 16.862 USD, while its 52-week range spans from 0.584 USD to 16.862 USD.

What Is Immunic (IMUX) Price Target According to Analysts?

The average 12-month price target for Immunic is 41.900 USD, with a high estimate of 85 USD and a low estimate of 19 USD. 11 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +152.71% Upside potential.

What Is the IMUX Premarket Price?

IMUX's last pre-market stock price is 15.720 USD. The pre-market share volume is 38.000, and the stock has decreased by -0.210, or -1.320%.

What Is the IMUX After Hours Price?

IMUX's last after hours stock price is 16.610 USD, the stock has decreased by 0.030, or 0.180%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.